olivLaw · US equity research
Tilray Brands, Inc. TLRY
Medicinal Chemicals & Botanical Products · SIC 2833 · Vertical: Medicinal Chemicals & Botanical Products (SIC 2833)
Tilray Brands is a global consumer products group spanning cannabis, beer and beverages, wellness and pharmaceutical distribution. The current focus is diversification: revenue rose 23% in the first quarter of fiscal 2027, and the BrewDog acquisition strengthened the beverage segment, while US cannabis regulation remains in flux.
At the close of 04 Nov 2026, Tilray Brands, Inc. (TLRY) stock was 2.96 USD (+11.70% on the day), with market capitalisation 437.5 m USD, beta 1.63, 52-week range 2.53–13.94 USD. Latest reported quarter (Q1 2027): revenue of 257.1 m USD (+22.7% YoY), net income of -43.1 m USD, diluted EPS -0.32 USD.
Data as of · AI analysis dated · Source: SEC filings and closing prices, computed by olivLaw.
Price history
Loading chart…
Technical reading
- RSI (14)
- 43.4
- weak (30–45)
- Bollinger (20, 2)
- 2.36 – 3.58
- in the lower half of the band · %B 0.49 · band width 40.9%
- SMA 50 / 200
- 3.66 / 5.39
- downtrend (price < SMA50 < SMA200)
- MACD (12, 26, 9)
- -0.29 / -0.32
- MACD above signal
Indicators describe past prices; on their own they do not predict direction. On our history the RSI ≤ 40 filter added no return (see the signals methodology).
Performance
| Company | S&P 500 | vs S&P 500 | Vertical median | |
|---|---|---|---|---|
| 1 month | −20.4% | −1.1% | −19.3 pp | — |
| 3 months | −33.2% | −0.5% | −32.7 pp | — |
| 6 months | −48.6% | +4.4% | −53.0 pp | — |
| Year to date | −67.2% | +12.3% | −79.5 pp | — |
| 1 year | −76.1% | +13.5% | −89.7 pp | −35.8% |
| 3 years | −84.6% | +76.4% | −161.0 pp | −14.7% |
| 5 years | −97.2% | +63.7% | −160.9 pp | — |
Price returns, dividends excluded.
Quarterly results
Latest quarter: Q1 2027 · 31 Aug 2026
Quarterly margins
Quarterly statements · USD
| Fiscal year | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 | Q3 '26 | Q4 '26 | Q1 '27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 211.0 m | 185.8 m | 224.5 m | 209.5 m | 217.5 m | 206.7 m | 281.7 m | 257.1 m |
| Cost of revenue | 149.7 m | 133.8 m | 156.9 m | 152.0 m | 160.0 m | 151.8 m | 191.2 m | 179.6 m |
| Gross profit | 61.2 m | 52.0 m | 67.6 m | 57.5 m | 57.5 m | 55.0 m | 90.5 m | 77.5 m |
| Research & development | 60.0 k | 85.0 k | 34.0 k | 41.0 k | 78.0 k | 62.0 k | 180.0 k | 89.0 k |
| Operating income | -42.2 m | -759.9 m | -1.4 bn | 2.1 m | -22.3 m | -26.4 m | -16.5 m | -24.1 m |
| Pre-tax income | -83.2 m | -792.3 m | -1.4 bn | -772.0 k | -40.0 m | -23.3 m | -24.1 m | -38.3 m |
| Income tax | 2.0 m | 1.2 m | -125.1 m | -2.3 m | 3.5 m | 2.0 m | 13.9 m | 1.7 m |
| Net income | -85.3 m | -789.4 m | -1.3 bn | -322.0 k | -44.9 m | -26.6 m | -49.6 m | -43.1 m |
| Diluted EPS | -0.99 | -8.69 | -13.01 ≈ | 0.00 | -0.41 | -0.24 | -0.42 ≈ | -0.32 |
| Operating cash flow | -40.7 m ≈ | -5.8 m ≈ | -12.8 m | -1.3 m | -8.5 m ≈ | -21.9 m ≈ | -37.3 m | -16.5 m |
| Capex | 5.4 m ≈ | 14.4 m ≈ | 6.3 m | — | — | — | — | — |
≈ derived quarter (cumulative difference / share-days average)
E/P over time
E/P = trailing-12-month diluted EPS / price at quarter end. E/P is the inverse of P/E and stays defined when earnings are negative.
Fiscal years
| Fiscal year | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 167.0 m | 210.5 m | 513.1 m | 628.4 m | 627.1 m | 788.9 m | 821.3 m | 915.5 m |
| Revenue YoY | +287.2% | +26.1% | +143.8% | +22.5% | −0.2% | +25.8% | +4.1% | +11.5% |
| Net income | -321.2 m | -271.1 m | -367.4 m | -476.8 m | -1.5 bn | -245.0 m | -2.2 bn | -121.4 m |
| Net income YoY | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable |
| Diluted EPS | -0.18 | -0.47 | -1.36 | -0.99 | -2.35 | -3.30 | -24.56 | -1.09 |
| Diluted EPS YoY | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable |
| net % | -192.3% | -128.8% | -71.6% | -75.9% | -231.6% | -31.1% | -266.3% | -13.3% |
| Free cash flow | -331.8 m | -174.0 m | -83.6 m | -211.3 m | -12.9 m | -60.2 m | -127.5 m | unavailable |
Reported results vs expectations
Loading…
Balance sheet & financial health
Fiscal year 2026 · 31 May 2026
- Cash
- 226.0 m USD
- Financial debt
- 129.2 m USD
- Net debt
- -96.8 m USD
- Equity
- 1.6 bn USD
- Total assets
- 2.3 bn USD
- Debt / equity
- 0.08x
- Current ratio
- 2.21x
- ROE
- -7.9%
- ROA
- -5.5%
- FCF margin
- unavailable
Financial statements (source on every figure)
Revenue and net income (USD)
Margins
Income statement · USD
| Line | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Revenue | 513.1 m | 628.4 m | 627.1 m | 788.9 m | 821.3 m | 915.5 m | SEC (XBRL)· 28 Jul 2026verified |
| Cost of revenue | 389.9 m | 511.6 m | 480.2 m | 565.6 m | 580.7 m | 655.0 m | SEC (XBRL)· 28 Jul 2026verified |
| Gross profit | 123.2 m | 116.8 m | 147.0 m | 223.4 m | 240.6 m | 260.4 m | SEC (XBRL)· 28 Jul 2026verified |
| Research & development | 830.0 k | 1.5 m | 682.0 k | 635.0 k | 284.0 k | 361.0 k | SEC (XBRL)· 28 Jul 2026verified |
| Operating income | -132.2 m | -610.4 m | -1.4 bn | -174.7 m | -2.3 bn | -63.0 m | SEC (XBRL)· 28 Jul 2026verified |
| Depreciation & amortisation | 67.8 m | 154.6 m | — | — | — | — | SEC (XBRL)· 28 Jul 2022verified |
| EBITDA | -64.3 m ≈ | -455.8 m ≈ | — | — | — | — | SEC (XBRL)· 28 Jul 2022derived |
| Interest expense | 30.9 m | 39.7 m | 46.6 m | 49.3 m | 41.3 m | 29.9 m | SEC (XBRL)· 28 Jul 2026verified |
| Pre-tax income | -345.0 m | -440.7 m | -1.5 bn | -249.0 m | -2.3 bn | -88.1 m | SEC (XBRL)· 28 Jul 2026verified |
| Income tax | -9.0 m | -6.5 m | -7.2 m | -26.6 m | -121.0 m | 17.1 m | SEC (XBRL)· 28 Jul 2026verified |
| Net income | -367.4 m | -476.8 m | -1.5 bn | -245.0 m | -2.2 bn | -121.4 m | SEC (XBRL)· 28 Jul 2026verified |
| Diluted EPS | -1.36 | -0.99 | -2.35 | -3.30 | -24.56 | -1.09 | SEC (XBRL)· 28 Jul 2026verified |
| Weighted average diluted shares | 269.5 m | 481.2 m | 618.0 m | 74.3 m | 89.0 m | 111.8 m | SEC (XBRL)· 28 Jul 2026verified |
≈ computed by olivLaw from the reported lines of the same year: Operating income + Depreciation & amortisation.
Balance sheet · USD
| Line | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Cash | 488.5 m | 415.9 m | 206.6 m | 228.3 m | 221.7 m | 226.0 m | SEC (XBRL)· 28 Jul 2026verified |
| Receivables | 87.3 m | 95.3 m | 86.2 m | 101.7 m | 121.5 m | 189.2 m | SEC (XBRL)· 28 Jul 2026verified |
| Inventories | 256.4 m | 245.5 m | 200.6 m | 252.1 m | 270.9 m | 301.2 m | SEC (XBRL)· 28 Jul 2026verified |
| Current assets | 883.6 m | 803.5 m | 773.0 m | 677.7 m | 688.6 m | 792.1 m | SEC (XBRL)· 28 Jul 2026verified |
| Property, plant & equipment, net | 650.7 m | 587.5 m | 429.7 m | 558.2 m | 568.4 m | 680.2 m | SEC (XBRL)· 28 Jul 2026verified |
| Goodwill | 2.8 bn | 2.6 bn | 2.0 bn | 2.0 bn | 752.4 m | 752.4 m | SEC (XBRL)· 28 Jul 2026verified |
| Intangibles (excl. goodwill) | 1.6 bn | 1.3 bn | 973.8 m | 915.5 m | 21.4 m | 42.8 m | SEC (XBRL)· 28 Jul 2026verified |
| Total assets | 6.0 bn | 5.4 bn | 4.3 bn | 4.2 bn | 2.1 bn | 2.3 bn | SEC (XBRL)· 28 Jul 2026verified |
| Accounts payable | 57.7 m | 68.6 m | 70.8 m | 105.4 m | 107.3 m | 114.5 m | SEC (XBRL)· 28 Jul 2026verified |
| Short-term debt | 8.7 m | 18.1 m | 23.4 m | 18.0 m | 7.2 m | 8.8 m | SEC (XBRL)· 28 Jul 2026verified |
| Long-term debt | 167.5 m | 117.9 m | — | — | — | 120.4 m | SEC (XBRL)· 08 Oct 2026verified |
| Current liabilities | 401.2 m | 280.3 m | 433.0 m | 299.2 m | 280.3 m | 358.4 m | SEC (XBRL)· 28 Jul 2026verified |
| Total liabilities | 1.6 bn | 1.0 bn | 977.3 m | 778.5 m | 584.8 m | 733.1 m | SEC (XBRL)· 28 Jul 2026verified |
| Equity | 4.5 bn | 4.4 bn | 3.3 bn | 3.4 bn | 1.5 bn | 1.6 bn | SEC (XBRL)· 28 Jul 2026verified |
Cash flow · USD
| Line | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -44.7 m | -177.3 m | 7.9 m | -30.9 m | -94.6 m | -69.1 m | SEC (XBRL)· 28 Jul 2026verified |
| Capex | 38.9 m | 34.1 m | 20.8 m | 29.2 m | 32.9 m | — | SEC (XBRL)· 29 Jul 2025verified |
| Free cash flow | -83.6 m ≈ | -211.3 m ≈ | -12.9 m ≈ | -60.2 m ≈ | -127.5 m ≈ | — | SEC (XBRL)· 29 Jul 2025derived |
| Investing cash flow | 46.1 m | -21.5 m | -285.1 m | 128.3 m | -46.7 m | -55.8 m | SEC (XBRL)· 28 Jul 2026verified |
| Financing cash flow | 124.3 m | 128.2 m | 70.2 m | -75.2 m | 133.5 m | 131.0 m | SEC (XBRL)· 28 Jul 2026verified |
≈ computed by olivLaw from the reported lines of the same year: Operating cash flow − Capex.
Computed indicators
Growth
Profitability
Returns
Balance sheet
Liquidity
Cash
Efficiency
Market and valuation
1 indicators that do not apply to the sector.
Valuation
olivLaw classification
- indicators available: 5 of at least 6
- score weight coverage: 35.4% of at least 60%
- valuation methods computed: 0 of at least 1
A scoring methodology on indicators and valuation, not investment advice.
Closing price
04 Nov 2026Source: olivLaw, closing series
Market cap: 437.5 m USD
Key indicators
Coverage and freshness
Score by group
35% · Insufficient data
Estimated value range
unavailable — no valuation method could be computed
Valuation assumptions are editorial choices, not measured; beta is not measured.
Valuation methods
- DCF (discounted cash flow)unavailable · the input exists, but its latest figure is far older than the latest reported period: not used
- Peers: EV/EBITDAunavailable · input data missing
- Peers: P/Eunavailable · the base of the ratio is not positive
- Dividend discount (DDM)unavailable · the company pays no dividend: a dividend model needs an explicit initiation assumption
no valuation method could be computed
Classification (SIC) comparables group by industry code, not by economic activity; the direct group is an editorial selection by activity. Members' multiples are on their own trailing twelve months, at their own latest close.
Assumptions (illustrative, editorial)
- Risk-free rate
- 4.3%
- Equity risk premium
- 5.0%
- Beta (default)
- 1.00
- Cost of equity
- 9.3%
- Terminal growth
- 2.5%
Factor scorecard
Insufficient data
Minimum-evidence gate: indicators available: 5 of at least 6; score weight coverage: 35.4% of at least 60%; valuation methods computed: 0 of at least 1
| Factor | Value | Score | Weight used |
|---|---|---|---|
| ROIC · Quality | -5.4% | 60 (vs peers) | 29% |
| Net margin · Quality | -17.1% | 27 (vs peers) | 18% |
| FCF conversion · Quality | unavailable | unavailable | — |
| Revenue CAGR 3Y · Growth | 13.4% | 100 (on a fixed band) | 24% |
| EPS CAGR 3Y · Growth | unavailable | unavailable | — |
| Net debt / EBITDA · Balance sheet | unavailable | unavailable | — |
| Interest coverage · Balance sheet | -3.0x | 0 (on a fixed band) | 18% |
| Current ratio · Balance sheet | 1.9x | 90 (on a fixed band) | 12% |
| P/E (TTM) · Valuation | unavailable | unavailable | — |
| EV/EBITDA · Valuation | unavailable | unavailable | — |
| FCF yield · Valuation | unavailable | unavailable | — |
| Shareholder yield (distributions) · Returns | unavailable | unavailable | — |
| Payout ratio (FCF) · Returns | unavailable | unavailable | — |
Factors without a value were dropped; the remaining weights were renormalised.
Score groups
- Balance sheet36/100 · 2/3 factors with a value
- Growth· partial100/100 · 1/2 factors with a value
- Quality48/100 · 2/3 factors with a value
- Returns· partialunavailable · 0/2 factors with a value
- Valuation· partialunavailable · 0/3 factors with a value
A «partial» group is computed from under half of its weight or from one factor: it is not a full assessment of the group.
Memo
Tilray Brands, Inc. (TLRY). Latest full fiscal year: 2026; data up to 2026-08-31.
Figures computed from the financial statements: revenue 915.5 m USD in 2026; YoY growth 11.5%; net margin -17.1%; ROE -10.4%.
Valuation cannot be computed from the available data.
Insufficient data for a verdict (indicators available: 5 of at least 6; score weight coverage: 35.4% of at least 60%; valuation methods computed: 0 of at least 1).
Text generated deterministically from the figures shown; no language model. Not investment advice.
What supports the thesis
- Revenue CAGR 3Y: 13.4%
- Current ratio: 1.9x
What contradicts it
- Net margin: -17.1%
- Interest coverage: -3.0x
Not assessed (insufficient data or a ratio without meaning): FCF conversion, EPS CAGR 3Y, Net debt / EBITDA, P/E (TTM), EV/EBITDA, FCF yield, Shareholder yield (distributions), Payout ratio (FCF).
Versus the vertical median
Medicinal Chemicals & Botanical Products (SIC 2833) · same industry (4-digit SIC) · compared with 15 companies
Multiples and returns vs the median
Price rebased to 100 (monthly, 5 years)
Companies in the vertical
| Market cap | P/E | ROE | Net margin | Revenue YoY | 1A / 3A | |
|---|---|---|---|---|---|---|
| TRLVTrulieve Cannabis Corp. | 2.2 bn | — | -48.2% | -41.8% | −0.4% | +115% / +109% |
| TLRYTilray Brands, Inc. | 437.5 m | — | -10.4% | -17.1% | +11.5% | −76% / −85% |
| USNAUsana Health Sciences, Inc. | 264.8 m | — | -4.2% | -2.4% | unavailable | −28% / −70% |
| NAGENiagen Bioscience, Inc. | 199.6 m | 21.3 | 13.3% | 8.4% | +29.9% | −63% / +81% |
| MDWDMediwound Ltd. | 182.3 m | — | -63.9% | -140.8% | −16.1% | −21% / +59% |
| FTLFFitlife Brands, Inc. | 76.8 m | 13.1 | 14.1% | 6.2% | +26.4% | −56% / −15% |
| BTMDbiote Corp. | 71.6 m | 11.8 | — | 3.2% | −2.5% | −55% / −75% |
| NAIINatural Alternatives International, Inc. | 24.3 m | — | -35.0% | -14.5% | +9.7% | −70% / −81% |
| MTEXMannatech Inc | 16.7 m | — | -1,490.1% | -6.9% | −8.3% | −8% / −3% |
| BONBon Natural Life Limited | 4.4 m | — | -3.9% | -10.7% | −21.7% | −39% / −99% |
| CGCCanopy Growth Corp | — | — | -39.9% | -79.2% | +5.8% | −36% / −87% |
| IMCCIM Cannabis Corp. | — | — | -1,496.2% | -20.7% | +1.3% | −99% / −99% |
| SNDLSNDL Inc. | — | — | -1.4% | -1.7% | +2.8% | −20% / −1% |
| ACBAurora Cannabis Inc | — | — | 0.3% | 0.5% | +27.3% | +14% / +14% |
| CRONCronos Group Inc. | — | — | 6.5% | 39.1% | +24.6% | +42% / +74% |
| GLASGlass House Brands Inc. | — | — | -31.2% | -16.3% | −9.4% | −57% / −45% |
1- and 3-year price returns: for TLRY from daily closes (the same as the performance table), for the other companies from month-end closes.
olivLaw engine forecast
The world engine ran after the company's latest material disclosure. Probabilities are of TOUCHING a level within the horizon (not closing there) and sit next to the random walk (p_rw), the no-information benchmark.
The engine has no published run for this company yet.
Valuation scenarios (editable assumptions)
Illustrative scenarios
Illustrative: not forecasts and without probabilities. Each case is one coherent set of assumptions, computed on today's figures.
Estimated price (USD)
| Estimated price | Bear | Base | Bull |
|---|---|---|---|
| 1 years | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable |
| 3 years | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable |
| 5 years | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable |
AI analysis
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
In brief
Tilray Brands is a global consumer products group spanning cannabis, beer and beverages, wellness and pharmaceutical distribution. The current focus is diversification: revenue rose 23% in the first quarter of fiscal 2027 3, and the BrewDog acquisition strengthened the beverage segment, while US cannabis regulation remains in flux 1.
SWOT
Strengths
- Diversification across four segments reduces dependence on a single market or regulatory framework 3.
- The company has an international infrastructure with EU-GMP certified facilities in Portugal and Germany 1.
- A portfolio of well-known brands, including BrewDog and Breckenridge, supports its position in beverages 1.
Weaknesses
Opportunities
Risks
- Dependence on licenceshigh
Cannabis operations rely on licences from Health Canada and other authorities, and a failure to renew could halt activity 1.
- US regulatory uncertaintyhigh
The cannabis rescheduling is contested in court and has no certain timetable, which could delay market entry plans 1.
- Competition in Canadamedium
The large number of producers and the illicit market could keep prices under pressure 1.
- Acquisition integrationmedium
Integrating BrewDog and other assets could bring operational difficulties and unforeseen costs 3.
- Currency fluctuationslow
Revenue from outside the US is in other currencies, and exchange rate moves can affect reported results 1.
Investment thesis
What would need to be true (bull case)
- Revenue grew 23% in the first quarter of fiscal 2027 and gross margin expanded, which could support higher profitability 3.
- The company holds leading positions in several categories and reported a stronger balance sheet with reduced debt 3.
- The Carlsberg agreement could open a new source of US beer revenue from 2027 1.
What would break the thesis
What to watch
- Delivery of the fiscal 2027 adjusted EBITDA guidancefiscal 2027
- Trend in Canadian cannabis market shareQ2 2027
- Timetable for US cannabis rescheduling2027
- Start of Carlsberg production in the USQ1 2027
Products, market & competition
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
The business
Tilray Brands, Inc. describes itself as a leading global lifestyle consumer products company, headquartered in Leamington and New York, with operations in Canada, the United States, Europe, Australia and Latin America 1. Its strategy aims to grow revenue through its brands, cost efficiency and international expansion, covering craft beer brands such as BrewDog and Sweetwater, medical and adult-use cannabis and hemp-based products 1. In fiscal 2026 the company completed the BrewDog acquisition, which turned its beverage platform from a US one into a global one 1.
In February 2026 the company entered an exclusive licensing agreement with Carlsberg Group, starting January 1, 2027, to produce and distribute Carlsberg branded beers in the US, with an initial five-year term and an automatic renewal subject to performance 1. It also entered a partnership in Panama, where it holds a 25% equity interest in a medical cannabis entity 1. For fiscal 2027 management reaffirmed adjusted EBITDA guidance of 68 to 75 million USD 3.
The structure has four reporting segments: beverage, cannabis, distribution and wellness 1. Results are seasonal and weighted toward the second half of the fiscal year, while in April 2026 the US government rescheduled certain cannabis products, with the broader process still ongoing 13.
Segments
Beverage
The beverage segment, the largest by revenue in the first quarter of fiscal 2027, includes craft beer brands and distilleries, and generated 253976 thousand USD in the last fiscal year 13. The BrewDog acquisition brought beverage revenue of 101.5 million USD in the first quarter, with a gross margin of 41% 3.
Market context
The addressed markets are craft beer in the US and the UK, medical and adult-use cannabis in Canada and Europe, and hemp-based foods 1. Germany remains the largest medical cannabis market in Europe, while the US framework is still under regulation 1.
The beer market in the US and UK is competitive, with consumer preferences shifting toward premium, no-alcohol and low-alcohol products 1. Prices in Canadian cannabis are under pressure, and the fixed excise tax per gram adds to the strain 1.
Trends
- US cannabis regulationmixed
The April 2026 rescheduling of certain cannabis products into Schedule III could open the US medical market, but the broader process is contested in court and the outcome is not certain 1.
- Price pressure in Canadaheadwind
Retailer consolidation has increased the bargaining power of large accounts, and competition among about 1,000 licensed producers compresses prices 1.
- Premiumization in beveragestailwind
Consumers are moving toward premium, non-alcoholic and low-alcohol products, and Tilray has launched lines such as Salty Sips and Clean Slate 1.
- International expansiontailwind
Gradual legalization of medical cannabis in Europe and Latin America creates opportunities, although the process is slower than originally expected 1.
Competitive position
In cannabis the company competes with about a thousand licensed producers in Canada and with the illicit market, whose operators have lower costs because they do not follow the rules 1. In beer, Tilray is the fourth largest US craft brewer and the number one craft brewer in the UK, competing with local and international brands 13.
- Canadian licensed producers
Roughly a thousand licensed producers compete in the Canadian cannabis market, which puts pressure on prices 1.
- Illicit cannabis market
Unlicensed operators offer lower prices and can draw legal consumers away 1.
- Large US craft brewers
Larger competitors have greater financial resources and marketing capabilities 1.
- European medical cannabis producers
Competition in Germany and Portugal for European medical markets is intense 1.
Links, dependencies and risks
Who the company is tied to, from its own SEC filings (customers, suppliers, production, partners, competitors, countries, regulation), from the 5 %+ holders' statements (13D/13G) and from what other companies say about it. Click a node for its evidence; on a listed company the graph moves to it.
Loading the links…
News & filings
In the press
- Will Tilray Brands Stock Take Off Before the End of 2026?Yahoo Finance — News · 21 Sept 2026 · EN
- Tilray Brands Has Lost More Than Half of Its Value in 2026, but Here's the Bullish Case for Taking a Chance on This Highly Risky StockYahoo Finance — News · 15 Sept 2026 · EN
- Better Cannabis Stock to Buy Right Now: Canopy Growth or Tilray Brands?Yahoo Finance — News · 02 Sept 2026 · EN
- Tilray Posted Record Fiscal 2026 Revenue -- Why Isn't the Stock Rallying?Yahoo Finance — News · 23 Aug 2026 · EN
The latest news item in our archive is from 21 Sept 2026; the newest SEC filing is from 08 Oct 2026. The press archive comes from the RSS feeds we follow and does not necessarily cover the latest event — the filings alongside do.
SEC filings
- Quarterly report08 Oct 2026
- Current report08 Oct 2026Results of operations · Financial statements and exhibits
- Proxy statement28 Sept 2026
- Current report14 Sept 2026Item 3.02
- Current report10 Aug 2026Item 3.02
- Annual report28 Jul 2026
- Current report28 Jul 2026Results of operations · Financial statements and exhibits
- Current report30 Jun 2026Item 3.02
- Current report09 Jun 2026Item 3.02
- Current report21 Apr 2026Other events · Financial statements and exhibits
Sources
- [1] Form 10-K, fiscal year ended 2026-05-31 · SEC / Tilray Brands, Inc. · 28 Jul 2026
- [2] Form 10-Q, quarter ended 2026-08-31 · SEC / Tilray Brands, Inc. · 08 Oct 2026
- [3] Form 8-K, results release (exhibit 99.1) · SEC / Tilray Brands, Inc. · 08 Oct 2026
Figures computed by olivLaw from SEC filings and closing prices; the qualitative analysis is AI-generated from cited sources. Not investment advice.